Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic haploidentical NK cell infusion as consolidation in pediatric acute myeloid leukemia
2015-001901-15Phase 2Active
- Sponsor
- Antonio Pérez MartÃnez
- Start
- Nov 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic haploidentical natural killer cells and aldesleukin in acute myeloid leukemia (AML), sponsored by Antonio Pérez MartÃnez. Primary endpoints: Probability of relapse and Objective response and minimal residual disease status. Started Nov 2015; status: active.
02
Drugs
allogeneic haploidentical natural killer cellsaldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2015-001901-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001901-15.